C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology ( ESMO ) Congress 2024

6 days ago

CFT1946 Is Well-Tolerated at All Dose Levels. No Dose-Limiting Toxicities ...

Ticker	Sentiment	Impact
CCCC	Neutral	17 %